Literature DB >> 219263

Prostatic adenocarcinoma of ductal origin.

L F Greene, G M Farrow, J M Ravits, F M Tomera.   

Abstract

Adenocarcinomas that arise from primary or secondary prostatic ducts have distinctive histopathologic features. The age of patients, symptoms, findings on digital rectal examination and determinations of serum acid and alkaline phosphatase are similar to those of patients with acinic carcinomas. Carcinomas of secondary ducts may be less responsive to endocrine manipulation and of greater malignancy than carcinomas of primary ducts. The course and survival of patients with ductal carcinomas treated conservatively are poor.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 219263     DOI: 10.1016/s0022-5347(17)56763-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  Ductal and Acinar Adenocarcinoma of Prostate: Morphological and Immunohistochemical Characterization.

Authors:  Faraz A Baig; Amna Hamid; Talat Mirza; Serajuddaula Syed
Journal:  Oman Med J       Date:  2015-05

2.  PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Authors:  Carlos L Morais; Mehsati Herawi; Antoun Toubaji; Roula Albadine; Jessica Hicks; George J Netto; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan
Journal:  Prostate       Date:  2015-07-14       Impact factor: 4.104

Review 3.  The update of prostatic ductal adenocarcinoma.

Authors:  Tantan Liu; Yingmei Wang; Ru Zhou; Haiyang Li; Hong Cheng; Jing Zhang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

4.  Pathologic stage of prostatic ductal adenocarcinoma at radical prostatectomy: effect of percentage of the ductal component and associated grade of acinar adenocarcinoma.

Authors:  Ali Amin; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2011-04       Impact factor: 6.394

5.  Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen.

Authors:  Todd M Morgan; Christopher J Welty; Funda Vakar-Lopez; Daniel W Lin; Jonathan L Wright
Journal:  J Urol       Date:  2010-10-16       Impact factor: 7.450

Review 6.  My approach to intraductal lesions of the prostate gland.

Authors:  M Pickup; T H Van der Kwast
Journal:  J Clin Pathol       Date:  2007-01-19       Impact factor: 3.411

7.  Expression of Zn-alpha 2-glycoprotein and PSP-94 in prostatic adenocarcinoma. An immunohistochemical study of 88 cases.

Authors:  S Gagnon; B Têtu; J Y Dubé; R R Tremblay
Journal:  Am J Pathol       Date:  1990-05       Impact factor: 4.307

8.  Ductal adenocarcinoma of the prostate: a Hong Kong case series.

Authors:  Raymond Wai Man Kan; Chi Fai Kan; Joseph Hon Ming Wong; Kenneth Kam Fung Fu; Chi Fai Ng; Steve Wai Hee Chan
Journal:  Int Urol Nephrol       Date:  2014-07-31       Impact factor: 2.370

9.  TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas.

Authors:  Tamara L Lotan; Antoun Toubaji; Roula Albadine; Mathieu Latour; Mehsati Herawi; Alan K Meeker; Angelo M DeMarzo; Elizabeth A Platz; Jonathan I Epstein; George J Netto
Journal:  Mod Pathol       Date:  2009-01-16       Impact factor: 7.842

10.  Ductal adenocarcinoma of the prostate: immunohistochemical findings and clinical significance.

Authors:  Jianjun Sha; Juanjie Bo; Jiahua Pan; Lianhua Zhang; Hanqing Xuan; Wei Chen; Dong Li; Zhaoliang Wang; Dongming Liu; Yiran Huang
Journal:  Onco Targets Ther       Date:  2013-10-24       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.